Lataa...
Certolizumab pegol
Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab’) of a monoclonal antibody that has been conjugated to polyethylene glyc...
Tallennettuna:
| Aineistotyyppi: | Artikkeli |
|---|---|
| Kieli: | en |
| Julkaistu: |
Landes Bioscience
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2840232/ https://ncbi.nlm.nih.gov/pubmed/20190560 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|